REPORT OUTLOOK
Market Size | CAGR | Dominating Region |
---|---|---|
USD 13.23 Billion By 2029 | 13.34% | North America |
By Resin Technology | By Technology | By End User |
---|---|---|
|
|
|
SCOPE OF THE REPORT
Companion Diagnostics Market Overview
The Companion Diagnostics Market Is Expected To Grow At 13.34% CAGR From 2021 To 2029. It Is Expected To Reach Above USD 13.23 Billion By 2029 From USD 3.5 Billion In 2020.
Companion diagnostics are in-vitro tests that provide information about patients’ therapeutic responses to a specific treatment. It is an in vitro medical device that provides information necessary for the safe and effective management of a corresponding drug or biological product. This diagnostic test assists a physician in determining whether a specific therapeutic product is beneficial to patients and can outweigh any potential serious side effects or risks.
The increase in various types of cancer among people is primarily driving market growth. As the number of clinical trials increases and the demand for next-generation sequencing grows, so will the growth of the companion diagnostic market. Another factor driving such growth is the importance of this market’s products in the production of various types of drugs.
The companion diagnostics market is expected to grow significantly during the forecast period, owing to an increase in R&D of targeted therapies, an increase in demand for precision medicine with rising attention in emerging economies, the discovery of new biomarkers for various conditions, and a higher number of unmet needs for cancer treatment.
With signs of progress in hereditary sequencing and genomics, it is now widely accepted that medications can generate varying results in different people. A superior understanding of an individual’s hereditary characteristics or biomarkers can advance the act of overseeing ‘the right medication, with impeccable timing, at the right portion, for the perfect individual’. Drug and biopharmaceutical companies are constantly working to implement patient-choice analytic systems in the early stages of medication development in order to provide targeted treatments to the right competitor. This contributes to the growth of the companion diagnostics market.
ATTRIBUTE | DETAILS |
Study period | 2020-2029 |
Base year | 2022 |
Estimated year | 2022 |
Forecasted year | 2022-2029 |
Historical period | 2018-2020 |
Unit | Value (USD Billion) |
Segmentation | By Offering, By Technology, By Indication, By End User, By Region |
By Resin Technology |
|
By Technology
 |
|
By Indication |
|
By End User |
|
By Region |
|
The introduction of COVID-19 has hampered consumption for companion diagnostics. In addition, key market players saw a significant drop in revenue as a result of the COVID-19 pandemic, owing to a reduction in testing volume and other factors. In regards to revenue, the market grew by 15.1% in 2020, compared to 19.8% in 2019.
Revenue generated by the major players decreased significantly in 2020. For example, Myriad Genetics, Inc. reported a 34.5% decrease in molecular diagnostics revenue in 2020 compared to 2019. In addition, Abbott Laboratories reported a 4.0% decrease in revenue from core laboratory diagnostics in 2020 compared to 2019.
However, the lifting of lockdown restrictions, stay-at-home orders in many countries, the introduction of novel diagnostic tests, and the re-establishment of the supply chain network were key factors in the recovery of testing in 2021. As a result, the resumption of cancer diagnostics testing and the introduction of new diagnostic tests boosted demand in 2021.
Companion Diagnostics Market Segment Analysis
The companion diagnostics market is segmented based on products, technology, indication, end user, and region, global trends and forecast.
On the basis of products, the market is segmented into assays, kits & reagents, software & services. Due to increase in demand for kits and reagents, the assays, kits and reagents segment is estimated to lead.
On the basis of technology, the market is segmented into polymerase chain reaction, next-generation sequencing, in situ hybridization, immunohistochemistry.
Based on technology, the pcr segment currently dominates the global market and is expected to do so throughout the forecast period. Cost effectiveness, high sensitivity, and specificity, which can be used for simple automated platforms, are some key factors driving market growth. Furthermore, the pcr, which is another key driver of this segment, can determine the sequencing of unknown etiologies of many diseases. However, the next generation sequencing segment is expected to grow rapidly during the forecast period due to key advantages such as higher sensitivity to detect low-frequency variants, shorter turnaround time for large sample volumes, the ability to sequence hundreds to thousands of genes or gene regions simultaneously, and so on.
On the basis of indication, the market is segmented into cancer, neurological diseases, infectious diseases, cardiovascular diseases.
The cancer segment is currently the largest revenue generator and is expected to grow significantly during the forecast period. Some key factors driving the growth of the cancer segment include increased cancer prevalence, increased r&d activities for cancer, increased unmet needs for cancer treatment, increased number of fda approved companion diagnostics, and increased patient awareness of personalized medicine.
Cancer research has discovered significant differences in gene sequence and expression patterns that can serve as the foundation for targeted therapy. Furthermore, many biomarkers for various cancers have been identified, for which companion diagnostics have been developed. Companion diagnostics are widely used in various types of cancer, including lung cancer, colorectal cancer, breast cancer, and blood cancer, which are the leading causes of death.
On the basis of end user, the market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, laboratories.
There is no denying that contract research organizations (cros) are becoming more important in the development of companion diagnostics. As the demand for personalized medicine grows, cros are uniquely positioned to assist pharmaceutical and biotechnology companies in developing customized treatments based on a patient’s unique genetic makeup.
Companion diagnostics are diagnostic tests used to identify patients who are likely to benefit from a specific treatment. They can also be used to track a patient’s response to therapy and make necessary adjustments. Cancer, cardiovascular disease, and infectious diseases are just a few of the conditions that can be treated with companion diagnostics.
Companion Diagnostics Market Players
Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major Companion Diagnostics market players.
Recent Developments:
23 January, 2023: QIAGEN Digital Insights announced launch of their enhanced QIAGEN CLC Genomics Workbench Premium that removes the data-analysis bottleneck of Next-Generation Sequencing by adding analysis speed to analyze and interpret Whole Genome Sequencing, Whole Exome Sequencing and Large Panel Sequencing data.
9 January, 2023: QIAGEN announced of having been completed the acquisition of Verogen, a leader in the use of Next-Generation Sequencing technologies to drive the future of human identification and forensic investigation.
Who Should Buy? Or Key stakeholders
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
- Investors
- Regulatory Authorities
Companion Diagnostics Market Regional Analysis
The Companion Diagnostics Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
North America is expected to lead the global companion diagnostics market. This could explain the high incidence rate of cancer and other chronic diseases, as well as the rising cost of healthcare in the area. Furthermore, market development is expected to drive an increase in the number of healthcare organisations working on generated genomic databases to better understand the human genome, as well as increased research activities in this area using companion diagnostic kits.
The European market for companion diagnostics is expected to be the second-largest during the review period. The expansion of the regional industry is expected to fuel the participation of a large number of companies as well as increased research and development activities aimed at improving personalised drug treatment for cancer patients. Furthermore, rising per capita income increases the preference for personalised treatment, fueling further consumer growth.
Because of the rapidly increasing number of cancer, cardiovascular, and neurological patients, Asia-Pacific is expected to be the fastest growing region. Furthermore, the rising prevalence of infectious diseases has a positive impact on business development. The high prevalence of cancer, increasing proteomics and genomics research, rising research funding, increasing investments by pharmaceutical and biotechnology firms, and rising awareness of personalised therapeutics in many APAC countries are expected to drive the growth of the APAC companion diagnostics market.
The Middle East and Africa market is expected to grow steadily due to an increase in cancer cases and a growing preference for customised drugs. The Middle East and Africa market is expected to grow steadily due to an increase in the number of hospitals and research labs, increased investment by healthcare firms, an increase in cancer cases, and increased drug discovery.
Key Market Segments: Companion Diagnostics Market
- Companion Diagnostics Market By Offering 2020-2029, (Usd Billion)
- Assays, Kits & Reagents
- Software & Services
Companion Diagnostics Market By Technology, 2020-2029, (Usd Billion)
- Polymerase Chain Reaction
- Next-Generation Sequencing
- In Situ Hybridization
- Immunohistochemistry
Companion Diagnostics Market By Indication, 2020-2029, (Usd Billion)
- Cancer
- Neurological Diseases
- Infectious Diseases
- Cardiovascular Diseases
Companion Diagnostics Market By End User, 2020-2029, (Usd Billion)
- Pharmaceutical & Biopharmaceutical Companies
- Contract Research Organizations
- Laboratories
Companion Diagnostics Market By Region, 2020-2029, (Usd Billion)
- North America
- Asia Pacific
- Europe
- South America
- Middle East And Africa
Important Countries In All Regions Are Covered.
Exactitude Consultancy Core Companion Diagnostics Services Key Objectives:
- Increasing sales and market share
- Developing new technology
- Improving profitability
- Entering new markets
- Enhancing brand reputation
Key Question Answered
- What is the expected growth rate of the companion diagnostics market over the next 7 years?
- Who are the major players in the companion diagnostics market and what is their market share?
- What are the end-user industries driving demand for market and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
- How is the economic environment affecting the companion diagnostics market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the companion diagnostics market?
- What is the current and forecasted size and growth rate of the global companion diagnostics market?
- What are the key drivers of growth in the companion diagnostics market?
- What are the distribution channels and supply chain dynamics in the companion diagnostics market?
- What are the technological advancements and innovations in the companion diagnostics market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the companion diagnostics market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the companion diagnostics market?
- What are the service offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK
- GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION), 2020-2029
- ASSAYS, KITS & REAGENTS
- SOFTWARE & SERVICES
- CORE COMPANION DIAGNOSTICS SERVICES
- GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION), 2020-2029
- POLYMERASE CHAIN REACTION
- NEXT-GENERATION SEQUENCING
- IN SITU HYBRIDIZATION
- IMMUNOHISTOCHEMISTRY
- GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION), 2020-2029
- CANCER
- NEUROLOGICAL DISEASES
- INFECTIOUS DISEASES
- CARDIOVASCULAR DISEASES
- GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION), 2020-2029
- PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- CONTRACT RESEARCH ORGANIZATIONS
- LABORATORIES
- GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION), 2020-2029
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES* (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
- QIAGEN
- AGILENT TECHNOLOGIES
- ROCHE
- ABBOTT LABORATORIES, INC.
- BIOMERIEUX
- VENTANA MEDICAL SYSTEMS
- MYRIAD GENETICS, INC.
- RESONANCE HEALTH LTD
- LEICA MICROSYSTEMS
- LIFE TECHNOLOGIES
- HOFFMANN-LA ROCHE LTD.
- ILLUMINA, INC.
- GUARDANT HEALTH
- THERMO FISHER SCIENTIFIC INC.
- DANAHER CORPORATION *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 2Â Â Â Â Â Â Â GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 3Â Â Â Â Â Â Â GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 4Â Â Â Â Â Â Â GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 5Â Â Â Â Â Â Â GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029
TABLE 6Â Â Â Â Â Â Â NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 7Â Â Â Â Â Â Â NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 8Â Â Â Â Â Â Â NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 9Â Â Â Â Â Â Â NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 10Â Â Â Â Â NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 11Â Â Â Â Â US COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 12Â Â Â Â Â US COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 13Â Â Â Â Â US COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 14Â Â Â Â Â US COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 15Â Â Â Â Â CANADA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 16Â Â Â Â Â CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 17Â Â Â Â Â CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 18Â Â Â Â Â CANADA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 19Â Â Â Â Â MEXICO COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 20Â Â Â Â Â MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 21Â Â Â Â Â MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 22Â Â Â Â Â MEXICO COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 23Â Â Â Â Â SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 24Â Â Â Â Â SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 25Â Â Â Â Â SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 26Â Â Â Â Â SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 27Â Â Â Â Â SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 28Â Â Â Â Â BRAZIL COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 29Â Â Â Â Â BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 30Â Â Â Â Â BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 31Â Â Â Â Â BRAZIL COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 32Â Â Â Â Â ARGENTINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 33Â Â Â Â Â ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 34Â Â Â Â Â ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 35Â Â Â Â Â ARGENTINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 36Â Â Â Â Â COLOMBIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 37Â Â Â Â Â COLOMBIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 38Â Â Â Â Â COLOMBIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 39Â Â Â Â Â COLOMBIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 40Â Â Â Â Â REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 41Â Â Â Â Â REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 42Â Â Â Â Â REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 43Â Â Â Â Â REST OF SOUTH AMERICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 44Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 45Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 46Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 47Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 48Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 49Â Â Â Â Â INDIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 50Â Â Â Â Â INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 51Â Â Â Â Â INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 52Â Â Â Â Â INDIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 53Â Â Â Â Â CHINA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 54Â Â Â Â Â CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 55Â Â Â Â Â CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 56Â Â Â Â Â CHINA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 57Â Â Â Â Â JAPAN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 58Â Â Â Â Â JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 59Â Â Â Â Â JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 60Â Â Â Â Â JAPAN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 61Â Â Â Â Â SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 62Â Â Â Â Â SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 63Â Â Â Â Â SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 64Â Â Â Â Â SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 65Â Â Â Â Â AUSTRALIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 66Â Â Â Â Â AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 67Â Â Â Â Â AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 68Â Â Â Â Â AUSTRALIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 69Â Â Â Â Â SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 70Â Â Â Â Â SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 71Â Â Â Â Â SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 72Â Â Â Â Â SOUTH-EAST ASIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 73Â Â Â Â Â REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 74Â Â Â Â Â REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 75Â Â Â Â Â REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 76Â Â Â Â Â REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 77Â Â Â Â Â EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 78Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 79Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 80Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 81Â Â Â Â Â ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 82Â Â Â Â Â GERMANY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 83Â Â Â Â Â GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 84Â Â Â Â Â GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 85Â Â Â Â Â GERMANY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 86Â Â Â Â Â UK COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 87Â Â Â Â Â UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 88Â Â Â Â Â UK COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 89Â Â Â Â Â UK COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 90Â Â Â Â Â FRANCE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 91Â Â Â Â Â FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 92Â Â Â Â Â FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 93Â Â Â Â Â FRANCE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 94Â Â Â Â Â ITALY COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 95Â Â Â Â Â ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 96Â Â Â Â Â ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 97Â Â Â Â Â ITALY COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 98Â Â Â Â Â SPAIN COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 99Â Â Â Â Â SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 100Â Â Â SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 101Â Â Â SPAIN COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 102Â Â Â RUSSIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 103Â Â Â RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 104Â Â Â RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 105Â Â Â RUSSIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 106Â Â Â REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 107Â Â Â REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 108Â Â Â REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 109Â Â Â REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 110Â Â Â MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 111Â Â Â MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 112Â Â Â MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 113Â Â Â MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 114Â Â Â MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 115Â Â Â UAE COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 116Â Â Â UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 117Â Â Â UAE COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 118Â Â Â UAE COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 119Â Â Â SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 120Â Â Â SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 121Â Â Â SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 122Â Â Â SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 123Â Â Â SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 124Â Â Â SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 125Â Â Â SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 126Â Â Â SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
TABLE 127Â Â Â REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY OFFERING (USD BILLION) 2020-2029
TABLE 128Â Â Â REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY (USD BILLION) 2020-2029
TABLE 129Â Â Â REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION (USD BILLION) 2020-2029
TABLE 130Â Â Â REST OF MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY END USER (USD BILLION) 2020-2029
LIST OF FIGURES
FIGURE 1 MARKET DYNAMICS
FIGURE 2 REPORT TIMELINES: YEARS CONSIDERED
FIGURE 3 BOTTOM-UP APPROACH
FIGURE 4 RESEARCH FLOW
FIGURE 5 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING USD BILLION, 2020-2029
FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2020-2029
FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2020-2029
FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2020-2029
FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2020-2029
FIGURE 10 PORTER’S FIVE FORCES MODEL
FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY OFFERING, USD BILLION, 2021
FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, USD BILLION, 2021
FIGURE 13 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION, USD BILLION, 2021
FIGURE 14 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER, USD BILLION, 2021
FIGURE 15 GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, USD BILLION, 2021
FIGURE 16 MARKET SHARE ANALYSIS
FIGURE 17 QIAGEN: COMPANY SNAPSHOT
FIGURE 18 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 19 ROCHE: COMPANY SNAPSHOT
FIGURE 20 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 21 BIOMERIEUX: COMPANY SNAPSHOT
FIGURE 22 VENTANA MEDICAL SYSTEMS: COMPANY SNAPSHOT
FIGURE 23 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
FIGURE 24 RESONANCE HEALTH LTD: COMPANY SNAPSHOT
FIGURE 25 LEICA MICROSYSTEMS: COMPANY SNAPSHOT
FIGURE 26 LIFE TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 27 F. HOFFMANN-L ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 28 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 29 GUARDANT HEALTH: COMPANY SNAPSHOT
FIGURE 30 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT
FAQ
The companion diagnostics market size had crossed USD 3.5 Billion in 2020 and will observe a CAGR of more than 13.34% up to 2029.
Major factors driving the companion diagnostics market growth include the significant growth of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.
The region’s largest share is in North America. Products manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.